Simone Fishburn

Before I fully go to @bluesky, a message for everywhere: VOTE. Vote like it matters, because it does. Get other people to vote. And most of all, take your kids to vote. Not less important than soccer practice, baseball games or Halloween. Vote.

And so, with heavy hearts we enter this Jewish New Year. And with more uncertainty and sadness than we have collectively felt for decades. But still the inevitable hope that this will mark a pivot to better days - wishing those who mark it, a good, healthy and peaceful Shana Tova

There's a long-standing discussion about whether research should be hypothesis-driven or hypothesis free. Omics are making unbiased discovery more realistic and industry is opening up to that. But academic incentives aren't aligned. @_Ktktktktk discusses: https://t.co/Iv5h3aIk2r

I had a fantastic conversation too! @johnvoyler occupies a rare position in biotech of having built a $20B+ company in under 15 years. Some of his lessons, via the podcast (available also on Apple, Spotify and more).

John V. Oyler @johnvoyler

I had a fantastic conversation with @FishburnSimone on the @BioCentury podcast. Thank you for having me as a guest. I truly enjoyed discussing @BeiGeneGlobal's global growth strategy and sharing insights about our innovative pipeline. Full podcast here: https://t.co/AKLJUumyW5 https://t.co/V4H464LSR6

RT @BeiGeneGlobal: Our Co-Founder, Chairman and CEO, @johnvoyler, recently joined @FishburnSimone on the @BioCentury podcast. They delved…

RT @BioCentury: The value in mapping genetics to the medical phenome: case studies from @VanderbiltU. Nancy Cox discusses insights from lon…

RT @BioCentury: John Oyler’s long game at @BeiGeneGlobal: Owning the process from clinical trials to manufacturing. The oncology company's…

RT @RegeneronDNA: @BioCentury We’re inspired by @Immunoplayers in his fireside chat about our joint Together for CHANGE initiative to addre…

RT @RegeneronDNA: RGC’s Gonçalo Abecasis lent his insights during an enlightening panel discussion at @BioCentury Grand Rounds on optimizin…

RT @jflier: This Harvard student speaks the truth. “Zionist” is not a slur. @Harvard students need to stop using it as one. ⁦@thecrimson⁩…

RT @BioCentury: Introducting BioCentury's Back to School 2024. Editor in Chief @FishburnSimone and colleagues drill down on picking the rig…

RT @davidaxelrod: What a heart-wrenching presentation at the DNC by the parents of Hersh Goldberg-Polin, the young hostage currently being…

RT @BioCentury: Building up B cells @Biogen — Jane Grogan discusses her plans for research at the biotech with @FishburnSimone on The #BioC…

RT @jeff_cranmer: In an exclusive conversation with @BioCentury, Jim Wilson describes how he plans to use newly launched GemmaBio as a vehi…

Calling on translational academics! Do you find it hard to meet #biotech VCs and pharmas? Do you have results and an idea that you'd like to showcase? BioCentury's Grand Rounds conference is designed for you. Sept 9-11, Nashville, TN. Find out more: https://t.co/Oiod4taCdY https://t.co/XjjLnSQZ3h

RT @BioCentury: Greg Verdine, Co-Founder, President & CEO of LifeMine Therapeutics and Professor of Chemistry at Harvard University is join…

AZ’s rise in oncology is probably one of biopharma’s all- time top turnaround stories. In this interview with @AstraZeneca oncology head @susanmgalbraith, we discuss what they did: https://t.co/K4ZvVZKsro